A high-risk medication reconciliation priority.
Personal insulin pumps require the same disciplined medication reconciliation and clinical oversight as other high-risk insulin therapies. Because a patient-owned pump may continue delivering insulin unless it is recognized and incorporated into the plan of care, early identification is essential. Aggregate quality reviews have identified recurring opportunities involving device recognition, medication reconciliation, required orders, pharmacy verification, glucose monitoring, reassessment after a change in clinical status, and communication during transitions of care. These lessons are presented to reinforce safe practice and are intentionally generalized to protect patient and staff confidentiality.
The central safety principle is that documentation of an insulin pump in the history alone is not sufficient. Identification of any personal insulin-delivery device must trigger a coordinated evaluation of the patient’s ability to self-manage, confirmation that the device is permitted under policy, establishment of hospital glucose monitoring, and clear communication among providers, nursing, and pharmacy. Continued pump use is appropriate only when all eligibility requirements are met. A meaningful change in cognition, judgment, clinical stability, glycemic control, device function, or ability to manage the pump requires immediate reassessment and, when indicated, transition to hospital-managed insulin therapy.
Bedside nursing safeguards: Identify personal insulin pumps and insulin-delivery patches during the initial skin and device assessment and confirm that the device is reflected in the medication reconciliation and plan of care. Verify that required orders, scheduled hospital point-of-care glucose monitoring, and pharmacy review are in place. Maintain awareness of boluses, cartridge changes, and infusion-site changes; communicate the presence of the pump during every handoff and transfer; and promptly escalate changes in mental status, judgment, glucose control, device function, or the patient’s ability to self-manage. Continuous glucose monitor readings may provide supplemental information but do not replace hospital point-of-care testing for insulin-dosing decisions.
Emergency department and admitting provider safeguards: During the initial evaluation and medication reconciliation, confirm whether the patient uses a personal insulin pump or insulin-delivery patch and determine whether continued self-management is clinically appropriate. Assess cognition, judgment, clinical stability, glycemic status, device function, ability to operate the pump independently, and availability of supplies. If pump use is appropriate, place the Insulin SC Insulin Pump order set and the Pharmacy Consult—Patient Own Insulin Pump, establish hospital glucose-monitoring orders, and ensure that bedside nursing is aware. If any exclusion criterion is present, discontinue self-management and initiate appropriately timed hospital-managed insulin therapy to avoid interruption of basal insulin.
Pharmacy safeguards: Review the ordered consultation before inpatient pump continuation, confirm that the device is eligible under policy, and verify and document relevant pump settings, insulin concentration, basal and bolus parameters, and glycemic targets. Identify discrepancies or safety concerns, communicate them directly to the provider and bedside nurse, and support transition planning when pump use is not appropriate. Across all disciplines, a personal pump should not be continued or restarted until eligibility has been reassessed, required orders and monitoring are active, pharmacy review is complete, and the plan is clearly understood by the care team.
Consistent use of these safeguards will reduce preventable insulin-related harm and support safe, coordinated care across every setting. Early identification, complete medication reconciliation, and clear interdisciplinary accountability are essential whenever a hospitalized patient uses a personal insulin pump.
Reference: Continuous Subcutaneous Insulin Infusion (CSII) Pump and Continuous Glucose Monitor Use—Inpatient Protocol. PolicyStat: https://phs-wapsph.policystat.com/policy/20968026/latest/
